Ciltacabtagene autoleucel vs Idecabtagene vicleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

Ciltacabtagene autoleucel

Marketed by Johnson & Johnson under a licence from Legend Biotech Corporation

Approved in Multiple MyelomaCAR-T (autologous cellular therapy)
Partial signal

NCT04181827 · Phase 3 · active, not recruiting

This was a large randomized phase 3 trial against active standard therapy, and its primary endpoint, progression-free survival, clearly favoured cilta-cel (hazard ratio 0.26, P<0.001). However, it was open-label: patients and doctors knew which treatment was given, so the evidence is rated below the top level.

Next expected readout: February 2027 · NCT04133636 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)): Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). (met)

Result source: NCT04181827

Idecabtagene vicleucel

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomacell therapy (autologous CAR-T)
Reliable signal

NCT03651128 · Phase 3 · completed

Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).

Next expected readout: May 2027 · NCT05393804 (registry estimate)

Reported efficacy

Progression-free survival (PFS): PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001) (met)

Result source: NCT03651128

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCiltacabtagene autoleucelIdecabtagene vicleucel
PFS, median—Trial running · NCT052570838.9bn 137NCT03361748
OS, median27.0bn 8NCT0354820728.3bn 137NCT03361748
ORR97.1%bn 68NCT03548207
2 other results
74.5%bn 137NCT03361748
VGPR or better96.6%bn 29NCT03548207
2 other results
—Not posted · NCT03651128
MRD negativity100%bn 18NCT03548207
2 other results
—Not posted · NCT03651128

PFS, median

Ciltacabtagene autoleucel
—Trial running · NCT05257083
Idecabtagene vicleucel
8.9bn 137NCT03361748

OS, median

Ciltacabtagene autoleucel
27.0bn 8NCT03548207
Idecabtagene vicleucel
28.3bn 137NCT03361748

ORR

Ciltacabtagene autoleucel
97.1%bn 68NCT03548207
2 other results
Idecabtagene vicleucel
74.5%bn 137NCT03361748

VGPR or better

Ciltacabtagene autoleucel
96.6%bn 29NCT03548207
2 other results
Idecabtagene vicleucel
—Not posted · NCT03651128

MRD negativity

Ciltacabtagene autoleucel
100%bn 18NCT03548207
2 other results
Idecabtagene vicleucel
—Not posted · NCT03651128
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Ciltacabtagene autoleucel: 7 of 9 rows · Idecabtagene vicleucel: 8 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCiltacabtagene autoleucel
Rows use multiple source trials
Idecabtagene vicleucel
Complete
responder rate · % of participants
No placebo or comparator arm
17.1% (n=82)a,b,c
NCT05347485 · Phase 2 · registry result, not featured evidence
34.3% (n=137)a,b,c
NCT03361748 · Phase 2
Duration of Response
time to event · months
No placebo or comparator arm
NA monthsd,e,a,b,c
NCT03548207 · Phase 1/2
show 2 more doses
NA months
NCT03548207 · Phase 1/2
NA months
NCT03548207 · Phase 1/2
11.04 monthse,a,b,c
NCT03361748 · Phase 2
ORR
responder rate · % of participants
No placebo or comparator arm
100% (n=8)d,e,a,b,c
NCT03548207 · Phase 1/2
show 1 more dose
97.1% (n=68)
NCT03548207 · Phase 1/2
74.5% (n=137)e,a,b,c
NCT03361748 · Phase 2
Overall Survival
time to event · months
No placebo or comparator arm
NA monthsd,e,a,b,c
NCT03548207 · Phase 1/2
show 2 more doses
27.04 months
NCT03548207 · Phase 1/2
NA months
NCT03548207 · Phase 1/2
28.25 monthse,a,b,c
NCT03361748 · Phase 2
PFS
time to event · months
No placebo or comparator arm
NA monthsd,e,a,b,c
NCT03548207 · Phase 1/2
show 2 more doses
NA months
NCT03548207 · Phase 1/2
NA months
NCT03548207 · Phase 1/2
8.9 monthse,a,b,c
NCT03361748 · Phase 2
Dropout rate
n/a: no completion milestonef
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
n/a: no completion milestonePhase 1b (US Population)
NCT03548207 · Phase 1/2
n/a: no completion milestonePhase 2 (Japan Population)
NCT03548207 · Phase 1/2
n/a: no completion milestonePhase 2 (US Population)
NCT03548207 · Phase 1/2
n/a: no completion milestone
NCT05347485 · Phase 2 · registry result, not featured evidence
73.7%g
NCT03361748 · Phase 2
show 1 more result
5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—f
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
—Phase 1b (US Population)
NCT03548207 · Phase 1/2
—Phase 2 (Japan Population)
NCT03548207 · Phase 1/2
—Phase 2 (US Population)
NCT03548207 · Phase 1/2
—
NCT05347485 · Phase 2 · registry result, not featured evidence
—g
NCT03361748 · Phase 2
show 1 more result
—
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
47.1%f
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
37.9%Phase 1b (US Population)
NCT03548207 · Phase 1/2
11.1%Phase 2 (Japan Population)
NCT03548207 · Phase 1/2
61.8%Phase 2 (US Population)
NCT03548207 · Phase 1/2
51.2%
NCT05347485 · Phase 2 · registry result, not featured evidence
78.8%g
NCT03361748 · Phase 2
show 1 more result
22.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
f
neutropenia 89.9%
cytokine release syndrome 62%
thrombocytopenia 54.3%
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
neutropenia 100%
cytokine release syndrome 89.7%
thrombocytopenia 86.2%
NCT03548207 · Phase 1/2
neutropenia 88.9%
cytokine release syndrome 77.8%
thrombocytopenia 77.8%
NCT03548207 · Phase 1/2
neutropenia 94.1%
cytokine release syndrome 86.8%
anaemia 83.8%
NCT03548207 · Phase 1/2
neutropenia 80.5%
anaemia 59.8%
cytokine release syndrome 57.3%
NCT05347485 · Phase 2 · registry result, not featured evidence
g
neutropenia 94.9%
cytokine release syndrome 80.3%
anaemia 75.9%
NCT03361748 · Phase 2
show 1 more result
lymphocyte count decreased 85%
neutrophil count decreased 77.5%
white blood cell decreased 72.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 1/2 versus Phase 2.
  6. fPopulation comparability has not been reviewed for 4 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ciltacabtagene autoleucel

PFS NA vs 11.79 PVd or DPd months
time to event · months
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
VGPR or Better 96.6% (n=29)
responder rate · % of participants
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
94.1% (n=68)
NCT03548207 · Phase 1/2
100% (n=8)
NCT03548207 · Phase 1/2
MRD Negative 100% (n=18)
responder rate · % of participants
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
89.7% (n=39)
NCT03548207 · Phase 1/2
75% (n=8)
NCT03548207 · Phase 1/2
Clinical Benefit 100% (n=29)
responder rate · % of participants
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 3 more results
97.1% (n=68)
NCT03548207 · Phase 1/2
100% (n=9)
NCT03548207 · Phase 1/2
59.8% (n=82)
NCT05347485 · Phase 2 · registry result, not featured evidence
Time to First Response 0.95 months
time to event · months
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
0.95 months
NCT03548207 · Phase 1/2
0.92 months
NCT03548207 · Phase 1/2
EQ-5D-5L Utility -0.1 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0 score @ 4wk
NCT03548207 · Phase 1/2
0 score @ 8wk
NCT03548207 · Phase 1/2
0 score @ 11.14wk
NCT03548207 · Phase 1/2
0 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
0 score @ 26.29wk
NCT03548207 · Phase 1/2
0.1 score @ 30.29wk
NCT03548207 · Phase 1/2
0.1 score @ 34.29wk
NCT03548207 · Phase 1/2
0.1 score @ 38.29wk
NCT03548207 · Phase 1/2
0.1 score @ 42.29wk
NCT03548207 · Phase 1/2
0 score @ 46.29wk
NCT03548207 · Phase 1/2
0.1 score @ 50.29wk
NCT03548207 · Phase 1/2
-0.1 score @ 54.29wk
NCT03548207 · Phase 1/2
-0.05 score @ 1wk
NCT03548207 · Phase 1/2
-0.06 score @ 4wk
NCT03548207 · Phase 1/2
-0.03 score @ 8wk
NCT03548207 · Phase 1/2
0.01 score @ 11.14wk
NCT03548207 · Phase 1/2
-0.04 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
-0.02 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.01 score @ 26.29wk
NCT03548207 · Phase 1/2
0.04 score @ 30.29wk
NCT03548207 · Phase 1/2
0.05 score @ 34.29wk
NCT03548207 · Phase 1/2
0.07 score @ 38.29wk
NCT03548207 · Phase 1/2
0.04 score @ 42.29wk
NCT03548207 · Phase 1/2
0.14 score @ 46.29wk
NCT03548207 · Phase 1/2
EQ-5D-5L VAS -6.7 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0.6 score @ 4wk
NCT03548207 · Phase 1/2
2.2 score @ 8wk
NCT03548207 · Phase 1/2
5.3 score @ 11.14wk
NCT03548207 · Phase 1/2
1.9 score @ 14.29wk
NCT03548207 · Phase 1/2
6.4 score @ 18.29wk
NCT03548207 · Phase 1/2
4.8 score @ 22.29wk
NCT03548207 · Phase 1/2
6.1 score @ 26.29wk
NCT03548207 · Phase 1/2
9.6 score @ 30.29wk
NCT03548207 · Phase 1/2
11 score @ 34.29wk
NCT03548207 · Phase 1/2
7.2 score @ 38.29wk
NCT03548207 · Phase 1/2
10 score @ 42.29wk
NCT03548207 · Phase 1/2
11.9 score @ 46.29wk
NCT03548207 · Phase 1/2
10.2 score @ 50.29wk
NCT03548207 · Phase 1/2
-2 score @ 54.29wk
NCT03548207 · Phase 1/2
-13.75 score @ 1wk
NCT03548207 · Phase 1/2
-0.75 score @ 4wk
NCT03548207 · Phase 1/2
-4.5 score @ 8wk
NCT03548207 · Phase 1/2
-3 score @ 11.14wk
NCT03548207 · Phase 1/2
-1.88 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.25 score @ 26.29wk
NCT03548207 · Phase 1/2
2.5 score @ 30.29wk
NCT03548207 · Phase 1/2
0 score @ 34.29wk
NCT03548207 · Phase 1/2
-2.5 score @ 38.29wk
NCT03548207 · Phase 1/2
-12.5 score @ 42.29wk
NCT03548207 · Phase 1/2
-10 score @ 46.29wk
NCT03548207 · Phase 1/2
PGI-S -0.3 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0.3 score @ 1wk
NCT03548207 · Phase 1/2
-0.3 score @ 4wk
NCT03548207 · Phase 1/2
-0.1 score @ 4wk
NCT03548207 · Phase 1/2
-0.3 score @ 8wk
NCT03548207 · Phase 1/2
0.3 score @ 8wk
NCT03548207 · Phase 1/2
-0.3 score @ 11.14wk
NCT03548207 · Phase 1/2
0 score @ 11.14wk
NCT03548207 · Phase 1/2
-0.3 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 14.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
-0.4 score @ 22.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 26.29wk
NCT03548207 · Phase 1/2
0.3 score @ 26.29wk
NCT03548207 · Phase 1/2
-0.2 score @ 30.29wk
NCT03548207 · Phase 1/2
0 score @ 30.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 34.29wk
NCT03548207 · Phase 1/2
0 score @ 34.29wk
NCT03548207 · Phase 1/2
-0.5 score @ 38.29wk
NCT03548207 · Phase 1/2
0 score @ 38.29wk
NCT03548207 · Phase 1/2
-0.2 score @ 42.29wk
NCT03548207 · Phase 1/2
0 score @ 42.29wk
NCT03548207 · Phase 1/2
-0.6 score @ 46.29wk
NCT03548207 · Phase 1/2
0 score @ 46.29wk
NCT03548207 · Phase 1/2
-0.9 score @ 50.29wk
NCT03548207 · Phase 1/2
-0.5 score @ 54.29wk
NCT03548207 · Phase 1/2
PGIC 2.7 score @ 4wk
absolute value · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 7 more results
2.8 score @ 4wk
NCT03548207 · Phase 1/2
2.5 score @ 8wk
NCT03548207 · Phase 1/2
2.9 score @ 8wk
NCT03548207 · Phase 1/2
2.2 score @ 11.14wk
NCT03548207 · Phase 1/2
2.5 score @ 11.14wk
NCT03548207 · Phase 1/2
2 score @ 14.29wk
NCT03548207 · Phase 1/2
2.4 score @ 14.29wk
NCT03548207 · Phase 1/2
Partial 9.8% (n=82)
responder rate · % of participants
No placebo or comparator arm
NCT05347485 · Phase 2 · registry result, not featured evidence
VGPR 14.6% (n=82)
responder rate · % of participants
No placebo or comparator arm
NCT05347485 · Phase 2 · registry result, not featured evidence
sCR 15.9% (n=82)
responder rate · % of participants
No placebo or comparator arm
NCT05347485 · Phase 2 · registry result, not featured evidence

Idecabtagene vicleucel

Time to Response 1 months
time to event · months
No placebo or comparator arm
NCT03361748 · Phase 2
Time to Progression 10.38 months
time to event · months
No placebo or comparator arm
NCT03361748 · Phase 2
VGPR or Better With MRD Negativity 40.9% (n=137)
responder rate · % of participants
No placebo or comparator arm
10^(-5) Sensitivity
NCT03361748 · Phase 2
EORTC QLQ-C30 Physical Functioning -0.4 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
2.1 score @ 4.33wk
NCT03361748 · Phase 2
9.8 score @ 13wk
NCT03361748 · Phase 2
13.9 score @ 26wk
NCT03361748 · Phase 2
13.1 score @ 39wk
NCT03361748 · Phase 2
13.3 score @ 52wk
NCT03361748 · Phase 2
12.8 score @ 78wk
NCT03361748 · Phase 2
3.8 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-C30 Global Health Status -4.7 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
4.3 score @ 4.33wk
NCT03361748 · Phase 2
8.8 score @ 13wk
NCT03361748 · Phase 2
12.5 score @ 26wk
NCT03361748 · Phase 2
15.7 score @ 39wk
NCT03361748 · Phase 2
14.1 score @ 52wk
NCT03361748 · Phase 2
10.6 score @ 78wk
NCT03361748 · Phase 2
7.1 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-MY20 Disease Symptoms -0.8 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
-10.2 score @ 4.33wk
NCT03361748 · Phase 2
-10.8 score @ 13wk
NCT03361748 · Phase 2
-12.6 score @ 26wk
NCT03361748 · Phase 2
-14.4 score @ 39wk
NCT03361748 · Phase 2
-15.7 score @ 52wk
NCT03361748 · Phase 2
-12 score @ 78wk
NCT03361748 · Phase 2
-13.1 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-MY20 Side Effects 2.5 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
0 score @ 4.33wk
NCT03361748 · Phase 2
-2.6 score @ 13wk
NCT03361748 · Phase 2
-4.7 score @ 26wk
NCT03361748 · Phase 2
-6.5 score @ 39wk
NCT03361748 · Phase 2
-4 score @ 52wk
NCT03361748 · Phase 2
-3.4 score @ 78wk
NCT03361748 · Phase 2
-3.2 score @ 104wk
NCT03361748 · Phase 2
EQ-5D-5L Index 0.0314 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
0.0528 score @ 4.33wk
NCT03361748 · Phase 2
0.0998 score @ 13wk
NCT03361748 · Phase 2
0.0974 score @ 26wk
NCT03361748 · Phase 2
0.1067 score @ 39wk
NCT03361748 · Phase 2
0.1097 score @ 52wk
NCT03361748 · Phase 2
0.1101 score @ 78wk
NCT03361748 · Phase 2
0.0383 score @ 104wk
NCT03361748 · Phase 2
CR/sCR 65.8% (n=38) @ 26wk
responder rate · % of participants
No placebo or comparator arm
Acheived CR/sCR by 6 Months post Infusion
NCT05032820 · Phase 2 · registry result, not featured evidence · combination · converted to % from 25 Participants as posted
Cumulative Incidence of Disease Progression 2.6% (n=38) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Response Upgrade 89.5% (n=38) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT05032820 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
Non Relapse Mortality 0% (n=38) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT05032820 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciltacabtagene autoleucel's landscape · Idecabtagene vicleucel's landscape